These results are outstanding. They shouldn’t be overlooked by buyers.
I understand that we have no clinical data from the CMAX Clinical Trial Facility For Phase I Study of Synthetic Antibiotic RECCE® 327 . But now we have these results from the Special Access Scheme you would have to think that this massively de-risks the investment in our company. We’ve basically got Phase I/II results from this announcement.
In the next month or two we’ll be expecting to see results back for Topical Phase I/II Human Clinical Trial Submission on burns infections at the Fiona Stanley Hospital. If we get positive results back from these, we’ve basically got a marketable product in 327…
I’m not one to count chickens before they’ve hatched but I’m feeling more and more confident that RCE will be pushing new price highs before the year is out.
Good luck to all holder. But I don’t think we’ll need it.
Ann: Positive Sinusitis Patient Update - Special Access Scheme, page-116
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
31.0¢ |
Change
0.010(3.33%) |
Mkt cap ! $89.39M | |||
| Open | High | Low | Value | Volume |
| 31.0¢ | 32.0¢ | 30.0¢ | $25.76K | 82.29K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 13550 | 30.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 31.0¢ | 18938 | 1 |
View Market Depth
| Last trade - 16.10pm 27/06/2025 (20 minute delay) ? |
| RCE (ASX) Chart |